Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.

Nature communications - 13 May 2016

Spoerke Jill M, Gendreau Steven, Walter Kimberly, Qiu Jiaheng, Wilson Timothy R, Savage Heidi, Aimi Junko, Derynck Mika K, Chen Meng, Chan Iris T, Amler Lukas C, Hampton Garret M, Johnston Stephen, Krop Ian, Schmid Peter, Lackner Mark R

Abstract excerpt

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in ESR1 and PIK3CA from ctDNA were assayed in clinical trial samples from ER+ metastatic breast cancer patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estradiol

Share to Estrogen Receptor alpha

Share to Estrogens

Share to Fulvestrant

Share to Indazoles

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 27174596
DOI: 10.1038/ncomms11579
PMCID: PMC4869259

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.PMID 27174596Read ↗

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read ↗

ESR1 mutations in breast cancerSemantic proximity Read ↗

Analysis of <i>ESR1</i> mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerSemantic proximity Read ↗

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.Semantic proximity Read ↗

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.Semantic proximity Read ↗

CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer.Semantic proximity Read ↗

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.Semantic proximity Read ↗

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.Semantic proximity Read ↗

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.Semantic proximity Read ↗

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.Semantic proximity Read ↗

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.